CANSINOBIO (06185) announced its performance in 2025, achieving revenue of approximately 1.059 billion yuan, a year-on-year increase of 28.43%.

CANSINOBIO (06185) announced its performance in 2025, with revenue of approximately 1.059 billion yuan, a year-on-year increase of 28.43%; the profit for the year reached 27.873 million yuan, turning losses into profits year-on-year; earnings per share were 0.11 yuan. The announcement stated that the turnaround to profitability was attributed to revenue growth, optimization of production costs, and improvement in operational efficiency. Since the launch of the quadrivalent meningococcal conjugate vaccine Manhixin and the bivalent meningococcal conjugate vaccine Menixi in 2022, these two vaccines have provided a more efficient and high-quality vaccine choice for preventing meningococcal diseases in infants and young children. In 2025, with the promotion and market introduction of meningococcal vaccine products, the sales revenue of the two meningococcal conjugate vaccines is expected to reach approximately 967.7 million yuan, a year-on-year increase of 21.9%. In addition, as of the date of this report, the drug supplementary application for Manhixin has been approved by the National Medical Products Administration, expanding the age range of the applicable population to "3 months to 6 years (83 months) old children", providing comprehensive protection for a wider range of children in the future. CANSINOBIO will also further promote the expansion application of Manhixin to the 7-59 age group, maximizing the value of its core product.